Investor Presentaiton

Reactogenicity sanofi Fast learnings from diverse clinical trials with mRNA and LNP Clinical trials Unmodified vs modified Mono- vs multi-valent Multiple targets Multiple LNPs (4+) Immunogenicity LNP3 (RSV) Multiple Sanofi LNP candidates LNP2 (RSV) LNP3 LNP1 (Flu) (Flu) LNP2 (Flu) LNP1 (Flu) Reactogenicity LNP2 (Flu) LNP with unmodified mRNA LNP with modified mRNA 86 Vaccines Investor Event

View entire presentation